Jenburkt Pharmaceuticals (524731) Q2 25/26 earnings summary

Executive summary

• Standalone unaudited financial results for the quarter and half year ended 30th September 2025 were approved and reviewed by the Board and Audit Committee on 28th October 2025.

Financial highlights

• Revenue from operations for Q2 FY26 was ₹4,555.76 lakhs, up from ₹4,121.59 lakhs in Q2 FY25 and ₹3,552.68 lakhs in Q1 FY26.

• Profit before tax for Q2 FY26 stood at ₹1,433.20 lakhs, compared to ₹1,252.28 lakhs in Q2 FY25 and ₹1,018.20 lakhs in Q1 FY26.

• Net profit after tax for Q2 FY26 was ₹1,016.34 lakhs, up from ₹960.05 lakhs in Q2 FY25 and ₹779.18 lakhs in Q1 FY26.

• Earnings per share (EPS) for Q2 FY26 was ₹23.03, compared to ₹21.75 in Q2 FY25 and ₹17.66 in Q1 FY26.

• Total comprehensive income for Q2 FY26 reached ₹988.21 lakhs, versus ₹1,060.57 lakhs in Q2 FY25.

Key financial ratios and metrics

• Gross margin and EBITDA not explicitly stated, but profit before tax and net profit both showed year-over-year and sequential growth.

• Paid-up equity share capital remained at ₹441.33 lakhs.